Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: A multicenter, double-blind, randomized, placebo-controlled trial

Neurology

Volumn 48, Issue 1, 1997, Pages 81-87

  Kurth, M C ^a   Adler, C H ^b   St Hilaire, M ^c   Singer, C ^d   Waters, C ^e   LeWitt, P ^f   Chernik, D A ^h   Dorflinger, E E ^g   Yoo, K ^g  

^a BARROW NEUROLOGICAL INSTITUTE   (United States)

^b MAYO CLINIC   (United States)

^c BOSTON UNIVERSITY   (United States)

^d UNIVERSITY OF MIAMI   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f SINAI GRACE HOSPITAL   (United States)

^g HOFFMANN LA ROCHE INC   (United States)

^h Section of Movement Disorders ^*

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOL METHYLTRANSFERASE INHIBITOR; LEVODOPA; TOLCAPONE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARKINSON DISEASE; PLASMA HALF LIFE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0031028464     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.48.1.81     Document Type: Article

References (13)

1. Cedarbaum J. Clinical pharmacokinetics of anti-parkinsonian drugs. Clin Pharmacokinet 1987;13:141-178.
2. Zuercher G, Dingemanse J, Da Prada M. RO 40-7592, a potent inhibitor of extracerebral and brain catechol-O-methyltransferase: preclinical and clinical findings. In: Agnoli A, Campanella G, eds. New developments in therapy of Parkinson's disease. Rome: John Libeey, 1991.
3. Roberts JW, Cora-Locatelli G, Bravi D, Amantea MA, Mouradian MM, Chase TN. Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients. Neurology 1993;43:2685-2688.
4. Limousin P, Pollak P, Gervason-Tournier CL, Hommel M, Perret JE. Ro 40-7592, a COMT inhibitor, plus levodopa in Parkinson's disease [letter]. Lancet 1993;341:1605.
5. Goetz C, Stebbins G, Shale H, et al. Utility of an objective dyskinesia rating scale for Parkinson's disease: inter- and intrarater reliability assessment. Mov Disord 1994;9:390-394.
6. Dingemanse J, Jorga K, Zuercher G, et al. Multiple dose clinical pharmacology of the catechol-O-methyltransferase inhibitor tolcapone in elderly subjects. Eur J Clin Pharmacol 1996; 50:47-55.
7. Pollak P, Limousin P, Gervason C, Perret J. Prolongation of levodopa-induced "on" motor periods by RO 40-7592, a catechol-O-methyltransferase inhibitor in Parkinson's disease. Ann Neurol 1993;32:316.
8. Da Prada M. New approaches to the treatment of age-related brain disorders. Can J Neurol Sci 1991;18:384-386.
9. Zuercher G, Dingemanse J, Da Prada M. Potent COMT inhibition by Ro 40-7592 in the periphery and in the brain: preclinical and clinical findings. Adv Neurol 1993;60:641-647.
10. Napolitano A, Zuercher G, Da Prada M. Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of L-dopa and dopamine in rats. Eur J Pharmacol 1995;273:215-221.
11. Olanow C, Fahn S, Muenter M, et al. A multicenter double-blind placebo-controlled trial of pergolide as adjunct to Sinemet in Parkinson's disease. Mov Disord 1994;9:40-47.
12. Hutton JT, Morris JL, Bush DF, Smith ME, Liss CL, Reines S. Multicenter controlled study of Sinemet CR vs Sinemet (25/100) in advanced Parkinson's disease. Neurology 1989;39: 67-72.
13. Gron U. Bromocriptine versus placebo in levodopa treated patients with Parkinson's disease. Acta Neurol Scand 1977; 56:269-273.